MedTrace Logo

Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy

NCT00702741 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2022-01-11

No results posted yet for this study

Summary

The objective of the present study is to establish the long-term safety of an intra-articular injection of human mesenchymal stem cells (hMSCs) (Chondrogen).

Conditions

  • Recovery Following Partial Medial Meniscectomy

Interventions

DRUG

Chondrogen

Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells

DRUG

Chondrogen

Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells

DRUG

Placebo

Intra-articular injection of Hyaluronan

Sponsors & Collaborators

  • Mesoblast International Sàrl

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00702741 on ClinicalTrials.gov